Products for Research Use Only

TPCA-1

CAT: 0804-HY-10074-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-10074-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
TPCA-1 is a potent and selective inhibitor of IKK-2 with IC50 of 17.9 nM. TPCA-1 is an effective inhibitor of STAT3 phosphorylation, DNA binding, and transactivation.
CAS Number
507475-17-4
UNSPSC
12352005
Hazard Statement
H302, H319
Target
Apoptosis; IKK; STAT
Type
Reference compound
Related Pathways
Apoptosis; JAK/STAT Signaling; NF-κB; Stem Cell/Wnt
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology; Cancer
Assay Protocol
https://www.medchemexpress.com/TPCA-1.html
Purity
99.66
Solubility
DMSO : ≥ 100 mg/mL
Smiles
O=C(C1=C(NC(N)=O)SC(C2=CC=C(F)C=C2)=C1)N
Molecular Formula
C12H10FN3O2S
Molecular Weight
279.29
Precautions
H302, H319
References & Citations
[1]Sachse F, et al. IKK-2 inhibitor TPCA-1 represses nasal epithelial inflammation in vitro.Rhinology. 2011 Jun;49 (2) :168-73.|[2]Podolin PL, et al. Attenuation of murine collagen-induced arthritis by a novel, potent, selective small molecule inhibitor of IkappaB Kinase 2, TPCA-1 (2-[ (aminocarbonyl) amino]-5- (4-fluorophenyl) -3-thiophenecarboxamide), occurs via reduction of proinflamm|[3]Nan J, et al. TPCA-1 is a direct dual inhibitor of STAT3 and NF-κB and regresses mutant EGFR-associated human non-small cell lung cancers. Mol Cancer Ther. 2014 Mar;13 (3) :617-29.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
IKK-β; STAT3

Alternative Products

CatalogName
A4602-5.1TPCA-1